Appeals Court Vacates Class Certification in Filana Therapeutics Securities Lawsuit

By Public Technologies12:18 (UTC), 20 October 2026 Updated

Fifth Circuit on Oct. 16, 2026, vacated class certification in a securities lawsuit against Filana Therapeutics and certain officers and employees.
The class covered purchasers or acquirers of the company's securities between Sept. 14, 2020, and Oct. 12, 2023.
The appeals court found the district court failed to evaluate market-inefficiency evidence or properly consider arguments about meme-stock dynamics.
The ruling did not determine whether the company's securities traded in an efficient or inefficient market.
Class certification proceedings will return to the U.S. District Court for the Western District of Texas.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Filana Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001437749-26-032971), on October 20, 2026, and is solely responsible for the information contained therein.